Varicella Prevention in the United States: a Review of Successes and Challenges
Overview
Authors
Affiliations
Objective: In 1995, the United States was the first country to introduce a universal 1-dose childhood varicella vaccination program. In 2006, the US varicella vaccine policy was changed to a routine 2-dose childhood program, with catchup vaccination for older children. The objective of this review was to summarize the US experience with the 1-dose varicella vaccination program, present the evidence considered for the policy change, and outline future challenges of the program.
Methods: We conducted a review of publications identified by searching PubMed for the terms "varicella," "varicella vaccine," and "herpes zoster." The search was limited to US publications except for herpes zoster; we reviewed all published literature on herpes zoster incidence.
Results: A single dose of varicella vaccine was 80% to 85% effective in preventing disease of any severity and >95% effective in preventing severe varicella and had an excellent safety profile. The vaccination program reduced disease incidence by 57% to 90%, hospitalizations by 75% to 88%, deaths by >74%, and direct inpatient and outpatient medical expenditures by 74%. The decline of cases plateaued between 2003 and 2006, and outbreaks continued to occur, even among highly vaccinated school populations. Compared with children who received 1 dose, in 1 clinical trial, 2-dose vaccine recipients developed in a larger proportion antibody titers that were more likely to protect against breakthrough disease and had a 3.3-fold lower risk for breakthrough disease and higher vaccine efficacy. Two studies showed no increase in overall herpes zoster incidence, whereas 2 others showed an increase.
Conclusions: A decade of varicella prevention in the United States has resulted in a dramatic decline in disease; however, even with high vaccination coverage, the effectiveness of 1 dose of vaccine did not generate sufficient population immunity to prevent community transmission. A 2-dose varicella vaccine schedule, therefore, was recommended for children in 2006. Data are inconclusive regarding an effect of the varicella vaccination program on herpes zoster epidemiology.
A cost benefit analysis of varicella vaccination in South Korea.
Lee Y, Choe Y Vaccine X. 2024; 19:100521.
PMID: 39070929 PMC: 11277761. DOI: 10.1016/j.jvacx.2024.100521.
Prevalence and progression of pneumonia in immunocompetent adults with varicella.
Cheng R, Lin F, Deng Z, Liang J, Li X, Lu M Virol J. 2024; 21(1):39.
PMID: 38336670 PMC: 10858607. DOI: 10.1186/s12985-024-02303-3.
The impact of varicella vaccination: A 2005-2019 interrupted time series analysis.
Miranda K, DeAntonio R, Norero X, Estripeaut D Hum Vaccin Immunother. 2024; 19(3):2278927.
PMID: 38175951 PMC: 10760379. DOI: 10.1080/21645515.2023.2278927.
Mo Z, Huang S, Qiu L, Li C, Yu X, Li M Lancet Reg Health West Pac. 2023; 34:100707.
PMID: 37283962 PMC: 10240365. DOI: 10.1016/j.lanwpc.2023.100707.
Varicella-Zoster Virus Myocarditis: Early Clinical Diagnosis and Outcome.
Cherukuri A, Belay N, Nasereldin D, Mohammed D, Mohamed S, Elkhazeen A Cureus. 2023; 15(4):e38015.
PMID: 37223180 PMC: 10204613. DOI: 10.7759/cureus.38015.